AstraZeneca PLC AZN
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About AZN
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines. The company operates primarily in the industries of oncology, rare diseases, cardiovascular, renal and metabolism, respiratory and immunology, vaccines, and infectious diseases. AstraZeneca generates revenue through sales of branded pharmaceutical products, strategic collaborations, licensing agreements, and research partnerships. Its largest revenue drivers have included oncology therapies such as Tagrisso, Imfinzi, Lynparza, and Enhertu, alongside medicines in cardiovascular and rare disease categories.
The company serves healthcare providers, hospitals, governments, and patients across both developed and emerging markets. AstraZeneca is recognized for its strong oncology pipeline, extensive biologics capabilities, and integration of advanced scientific platforms including antibody-drug conjugates, cell therapies, and precision medicine technologies. AstraZeneca was formed in 1999 through the merger of Sweden-based Astra AB and the UK-based Zeneca Group. The company expanded significantly through acquisitions including MedImmune, Alexion Pharmaceuticals, and partnerships with biotechnology firms and academic institutions, helping evolve it into one of the world’s largest research-driven pharmaceutical companies.
Business Operations
AstraZeneca organizes its operations around major therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), Rare Disease, and Vaccines & Immune Therapies. Revenue is primarily generated from global pharmaceutical sales, with oncology representing the company’s largest business segment by revenue based on recent annual reporting. The company maintains extensive research and development operations supported by manufacturing facilities and commercial infrastructure across North America, Europe, Asia, and emerging markets. AstraZeneca also earns collaboration and milestone revenue through alliances with biotechnology and pharmaceutical companies.
The company controls significant scientific and manufacturing assets, including biologics development capabilities through MedImmune and rare disease expertise through Alexion Pharmaceuticals. AstraZeneca has major strategic partnerships with companies such as Daiichi Sankyo for oncology products including Enhertu and Datroway, and collaborations with Merck & Co. involving Lynparza and Koselugo in certain markets. AstraZeneca operates globally through subsidiaries and regional business units, with substantial operations in the United States, Europe, and China. According to publicly available filings and investor materials, the company continues to invest heavily in research infrastructure, clinical development programs, and digital health technologies.
Strategic Position & Investments
AstraZeneca’s strategic direction centers on expanding its leadership in oncology and rare diseases while strengthening its broader biopharmaceutical portfolio. The company has emphasized high-growth therapeutic areas, biologics, precision medicine, and next-generation therapeutics such as antibody-drug conjugates and cell therapies. A major strategic milestone was the acquisition of Alexion Pharmaceuticals in 2021, which significantly expanded AstraZeneca’s rare disease portfolio and immunology capabilities. AstraZeneca has also invested heavily in oncology collaborations, particularly with Daiichi Sankyo, to strengthen its position in targeted cancer therapies.
The company continues to prioritize research and development investment, with annual R&D expenditures among the highest in the pharmaceutical industry according to company filings and major financial publications. AstraZeneca has pursued manufacturing expansion projects in the United States, Europe, and Asia to support biologics and advanced therapy production. The company is also active in emerging sectors including artificial intelligence-assisted drug discovery, genomics, and precision diagnostics through collaborations with technology firms, healthcare institutions, and biotechnology companies. Public disclosures indicate continued focus on long-term pipeline development and geographic expansion in high-growth healthcare markets.
Geographic Footprint
AstraZeneca is headquartered in Cambridge, United Kingdom, and operates in more than 100 countries globally. The company maintains substantial commercial, manufacturing, and research operations across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. The United States represents one of AstraZeneca’s largest individual markets by revenue, while China has become a major strategic growth region supported by local manufacturing, research partnerships, and commercial expansion.
The company’s global research network includes major R&D centers in the United Kingdom, United States, and Sweden, alongside manufacturing facilities distributed internationally. AstraZeneca also maintains strong market positions across Europe and expanding influence in emerging economies through localized operations and healthcare partnerships. Publicly available annual reports and regulatory filings indicate the company continues to invest in international supply chain resilience, regional clinical trial infrastructure, and market-specific healthcare collaborations.
Leadership & Governance
AstraZeneca’s leadership structure combines scientific, commercial, and operational expertise, with governance overseen by a board of directors and executive leadership team. The company’s strategy has emphasized science-led innovation, disciplined capital allocation, and long-term investment in research-driven growth. AstraZeneca’s leadership has consistently communicated a focus on transforming the company into a leading global biopharmaceutical innovator through pipeline expansion and targeted acquisitions.
Key executives include:
- Pascal Soriot – Chief Executive Officer
- Aradhana Sarin – Chief Financial Officer
- Susan Galbraith – Executive Vice President, Oncology Hematology R&D
- Ruud Dobber – Executive Vice President, BioPharmaceuticals Business Unit
- Marc Dunoyer – Chief Strategy Officer and Chief Executive Officer, Alexion
- Mene Pangalos – Executive Vice President, BioPharmaceuticals R&D
- Tom Keith-Roach – President, AstraZeneca US and Executive Vice President, US Business
- Leif Johansson – Chair of the Board of Directors
The company’s governance framework and executive structure are described in annual reports, corporate governance disclosures, and regulatory filings including SEC filings and AstraZeneca annual reports. Leadership information is consistent across company disclosures and major financial reporting sources.